Abstract
Wnt/β-catenin signaling pathway plays an important role in embryogenesis, stem cell maintenance, tumorigenesis and aging. Here, we show that RNA-binding protein, coding region determinant-binding protein (CRD-BP) (a transcriptional target of Wnt signaling pathway), is highly expressed in primary human malignant melanomas and melanoma cell lines with activated Wnt/β-catenin signaling pathway. Upregulation of CRD-BP is associated with an elevated level of β-TrCP1 ubiquitin ligase receptor and activation of nuclear transcriptional factors-kappa B (NF-κB) signaling. Knockdown of CRD-BP inhibits NF-κB activity, induces apoptosis, and suppresses proliferation and tumorigenic properties of melanoma cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Basseres DS, Baldwin AS . (2006). Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817–6830.
Bhatia N, Herter JR, Slaga TJ, Fuchs SY, Spiegelman VS . (2002). Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NF-kappaB. Oncogene 21: 1501–1509.
Chin L, Garraway LA, Fisher DE . (2006). Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20: 2149–2182.
Dimitriadis E, Trangas T, Milatos S, Foukas PG, Gioulbasanis I, Courtis N et al. (2007). Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. Int J Cancer 121: 486–494.
Doyle GA, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD, Ross J . (1998). The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res 26: 5036–5044.
Doyle GA, Bourdeau-Heller JM, Coulthard S, Meisner LF, Ross J . (2000). Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein. Cancer Res 60: 2756–2759.
Fuchs SY, Spiegelman VS, Kumar KG . (2004). The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23: 2028–2036.
Giles RH, van Es JH, Clevers H . (2003). Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1–24.
Gilmore TD . (2006). Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680–6684.
Herlyn M . (2006). Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Int J Cancer 118: 523–526.
Hussein MR, Haemel AK, Wood GS . (2003). Apoptosis and melanoma: molecular mechanisms. J Pathol 199: 275–288.
Ioannidis P, Mahaira L, Papadopoulou A, Teixeira MR, Heim S, Andersen JA et al. (2003). CRD-BP: a c-Myc mRNA stabilizing protein with an oncofetal pattern of expression. Anticancer Res 23: 2179–2183.
Ioannidis P, Trangas T, Dimitriadis E, Samiotaki M, Kyriazoglou I, Tsiapalis CM et al. (2001). C-MYC and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in benign and malignant mesenchymal tumors. Int J Cancer 94: 480–484.
Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M et al. (2007). Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene 26: 1954–1958.
Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC . (1999). A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19: 1262–1270.
Noubissi FK, Elcheva I, Bhatia N, Shakoori A, Ougolkov A, Liu J et al. (2006). CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling. Nature 441: 898–901.
Prokipcak RD, Herrick DJ, Ross J . (1994). Purification and properties of a protein that binds to the C-terminal coding region of human c-myc mRNA. J Biol Chem 269: 9261–9269.
Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER . (1999). Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154: 325–329.
Ross J, Lemm I, Berberet B . (2001). Overexpression of an mRNA-binding protein in human colorectal cancer. Oncogene 20: 6544–6550.
Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P . (1997). Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790–1792.
Runge S, Nielsen FC, Nielsen J, Lykke-Andersen J, Wewer UM, Christiansen J . (2000). H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein. J Biol Chem 275: 29562–29569.
Shattuck-Brandt RL, Richmond A . (1997). Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res 57: 3032–3039.
Smalley KS, Herlyn M . (2004). Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. J Invest Dermatol 123: xvi–xvii.
Soldatenkov VA, Dritschilo A, Ronai Z, Fuchs SY . (1999). Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. Cancer Res 59: 5085–5088.
Sparanese D, Lee CH . (2007). CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease. Nucleic Acids Res 35: 1209–1221.
Spiegelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z, Fuchs SY . (2000). Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell 5: 877–882.
Spiegelman VS, Tang W, Chan AM, Igarashi M, Aaronson SA, Sassoon DA et al. (2002). Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J Biol Chem 277: 36624–36630.
Ueda Y, Richmond A . (2006). NF-kappaB activation in melanoma. Pigment Cell Res 19: 112–124.
Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J et al. (2006). RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25: 1456–1468.
Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV et al. (2008). c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27: 1905–1915.
Weeraratna AT . (2005). A Wnt-er wonderland--the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev 24: 237–250.
Yang J, Richmond A . (2001). Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 61: 4901–4909.
Acknowledgements
We thank Drs N Maddodi, S Devi, J Ross, P Robbins, K Kinzler and B Vogelstein for their generous gifts of reagents, S Reagan-Shaw for statistical analysis, Drs V Setaluri and S Fuchs for critical reading of the paper, and Dr K Spiegelman and Ms I Larsen for help with the paper preparation. This study was supported by NCI Grant CA121851 (to VSS).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Elcheva, I., Tarapore, R., Bhatia, N. et al. Overexpression of mRNA-binding protein CRD-BP in malignant melanomas. Oncogene 27, 5069–5074 (2008). https://doi.org/10.1038/onc.2008.141
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.141
Keywords
This article is cited by
-
Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells
Experimental Hematology & Oncology (2023)
-
IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis
Oncogene (2023)
-
The biological function of IGF2BPs and their role in tumorigenesis
Investigational New Drugs (2021)
-
Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis
Oncogene (2019)
-
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer
Journal of Hematology & Oncology (2018)